The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Routine tumor next-generation sequencing (NGS) to identify rare germline lung cancer risk mutations in EGFR and ERBB2.
 
Ruthia Chen
No Relationships to Disclose
 
Diane R. Koeller
No Relationships to Disclose
 
Lynette M. Sholl
Consulting or Advisory Role - Genentech
Travel, Accommodations, Expenses - Mirati Therapeutics
Other Relationship - Research to Practice
 
Michael S. Rabin
Consulting or Advisory Role - Bayer
 
Matthew B. Yurgelun
Research Funding - Myriad Genetics
 
Anu B. Chittenden
No Relationships to Disclose
 
Judy Ellen Garber
Consulting or Advisory Role - Biogen; GTx (I); Helix BioPharma; Novartis (I); pfizer; pfizer (I); Pfizer (I); Sequenom; SV Life Sciences (I)
Research Funding - Ambry Genetics; Myriad Genetics; Novartis (I); Pfizer (I)
 
Geoffrey R. Oxnard
Honoraria - AstraZeneca; Chugai Pharma
Consulting or Advisory Role - ARIAD; AstraZeneca; Boehringer Ingelheim; Genentech/Roche; Inivata; Sysmex; Takeda
Patents, Royalties, Other Intellectual Property - DFCI has a patent pending titled "Non-invasive blood-based monitoring of genomic alterations in cancer", on which I am a co-author. (Inst)